文献速递临床试验与 GCP

早期给予地塞米松对无急性低氧性呼吸衰竭的COVID-19肺炎患者发生急性呼吸窘迫综合征风险的影响(EARLY-DEX COVID-19):随机对照试验研究方案

Effect of EARLY administration of DEXamethasone in patients with COVID-19 pneumonia without acute hypoxemic respiratory failure and risk of development of acute respiratory distress syndrome (EARLY-DEX COVID-19): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2022-09-15

EARLY-DEX COVID-19是一项多中心、随机、对照、平行、开放标签试验,计划纳入252例入院时无需补充氧气但有急性呼吸窘迫综合征(ARDS)发生风险的成人COVID-19肺炎患者,随机接受地塞米松6 mg每日一次共7天或标准治疗,主要结局为入组后30天内发生中度及以上ARDS与全因死亡率的复合终点。

要点

  • RECOVERY试验显示地塞米松降低需要补充氧气或侵入性机械通气的COVID-19住院患者28天死亡率。
  • 研究假设:对无需额外氧气但有重症进展风险的COVID-19肺炎患者早期使用地塞米松可能减少ARDS发生并降低死亡。
  • ARDS发生风险定义为乳酸脱氢酶>245 U/L、C反应蛋白>100 mg/L和淋巴细胞计数<0.80×10^9/L。

核心结论

  • 若假设成立,本研究结果将为无需额外氧气且有重症进展风险的COVID-19肺炎这一特定亚组患者的管理和病程提供更多见解。

研究设计与样本

  • 多中心、随机、对照、平行、开放标签试验,计划纳入252例入院时无需补充氧气但有ARDS发生风险的成人COVID-19肺炎患者。
  • 符合条件的患者随机接受地塞米松或标准治疗,地塞米松组剂量为6 mg每日一次共7天。
  • 主要结局为入组后30天内发生中度及以上ARDS与全因死亡率的复合终点。

主要发现

  • RECOVERY试验中,地塞米松与标准治疗相比降低需要补充氧气或侵入性机械通气的疑似或确诊COVID-19住院患者28天死亡率。
  • 证据显示30%的COVID-19轻症患者在就诊后会进展为ARDS,尤其是检测到与COVID-19疾病进展相关的实验室炎症生物标志物的患者。

关键数值与推荐

  • ARDS发生风险定义为乳酸脱氢酶>245 U/L、C反应蛋白>100 mg/L和淋巴细胞计数<0.80×10^9/L。
  • 地塞米松组剂量为6 mg每日一次共7天。
  • 主要结局为入组后30天内发生中度及以上ARDS与全因死亡率的复合终点。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Corticosteroids are one of the few drugs that have shown a reduction in mortality in coronavirus disease 2019 (COVID-19). In the RECOVERY trial, the use of dexamethasone reduced 28-day mortality compared to standard care in hospitalized patients with suspected or confirmed COVID-19 requiring supplemental oxygen or invasive mechanical ventilation. Evidence has shown that 30% of COVID-19 patients with mild symptoms at presentation will progress to acute respiratory distress syndrome (ARDS), particularly patients in whom laboratory inflammatory biomarkers associated with COVID-19 disease progression are detected. We postulated that dexamethasone treatment in hospitalized patients with COVID-19 pneumonia without additional oxygen requirements and at risk of progressing to severe disease might lead to a decrease in the development of ARDS and thereby reduce death. METHODS/DESIGN: This is a multicenter, randomized, controlled, parallel, open-label trial testing dexamethasone in 252 adult patients with COVID-19 pneumonia who do not require supplementary oxygen on admission but are at risk factors for the development of ARDS. Risk for the development of ARDS is defined as levels of lactate dehydrogenase > 245 U/L, C-reactive protein > 100 mg/L, and lymphocyte count of < 0.80 × 109/L. Eligible patients will be randomly assigned to receive either dexamethasone or standard of care. Patients in the dexamethasone group will receive a dose of 6 mg once daily during 7 days. The primary outcome is a composite of the development of moderate or more severe ARDS and all-cause mortality during the 30-day period following enrolment. DISCUSSION: If our hypothesis is correct, the results of this study will provide additional insights into the management and progression of this specific subpopulation of patients with COVID-19 pneumonia without additional oxygen requirements and at risk of progressing to severe disease. TRIAL REGISTRATION: ClinicalTrials.gov NCT04836780. Registered on 8 April 2021 as EARLY-DEX COVID-19.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Franco-Moreno A, Acedo-Gutiérrez MS, Martín NL, et al. Effect of EARLY administration of DEXamethasone in patients with COVID-19 pneumonia without acute hypoxemic respiratory failure and risk of development of acute respiratory distress syndrome (EARLY-DEX COVID-19): study protocol for a randomized controlled trial. Trials. 2022. PMID: 36109825. doi:10.1186/s13063-022-06722-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。